Despite the profitability miss, FY 23/24 guidance unchanged
09/02/24 -"CZM’s Q1 profitability fell short of expectations. Growth was once again led by Microsurgery, while Ophthalmology ended on a flat note. As expected, profitability was under pressure. Nonetheless, FY ..."
Pages
69
Language
English
Published on
09/02/24
You may also be interested by these reports :
14/09/26
Equity markets ended lower on the week ending September 11 as the renewed surge in energy prices revived inflation concerns and pushed bond yields ...
11/09/26
MedTech sector momentum has finally turned constructive in recent weeks, a welcome change after a multi-year stretch of post-covid destocking, supply ...
07/09/26
We have revised our estimates upwards and removed the 20% discount previously applied to the peer-based valuation. This optimism is supported by ...
04/09/26
Bastide ended FY25/26 above its revenue target, with Q4 organic growth recovering as the VPH headwind faded, confirming the one-off nature of the ...